Literature DB >> 25372319

Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases.

Laure Van Bol1, Anas Alami, Fleur S Benghiat, Florence Rasquin.   

Abstract

PURPOSE: To describe spectral domain optical coherence tomography features in two cases of early deferoxamine induced retinal toxicity.
METHODS: Two patients complained of sudden bilateral visual loss and dyschromatopsia. Both suffered from acute myelocytic leukemia with severe aplastic anemia and were treated with intravenous deferoxamine for 1 month. First ophthalmologic exploration and follow-up included fundoscopic examination, fluorescence angiography, fundus autofluorescence, and spectral domain optical coherence tomography.
RESULTS: Initially, both patients presented with a decreased visual acuity, inferior to 20/100. Fundus examination revealed a loss of transparency of the outer retina in the two cases. Autofluorescence pictures displayed hypoautofluorescence in the macular area, whereas fluorescein angiography unveiled an annular hyperfluorescence staining in the macular zone. Spectral domain optical coherence tomography showed a serous detachment of the neuroepithelium associated with photoreceptor outer segment elongation. Deferoxamine toxicity was immediately suspected and therapy promptly interrupted. One week later, both patients recovered visual acuity of 20/20 but retinal pigment epithelium (RPE) mottling was noticed in the macular areas. Spectral domain optical coherence tomography monitoring showed a progressive resolution of serous retinal detachment. Elongation of the photoreceptor outer segment disappeared but the RPE remained thickened, interrupted, and fragmented at different macular loci.
CONCLUSION: Serous detachment of the neuroepithelium associated with photoreceptor outer segment elongation in the early stage of deferoxamine maculopathy is described for the first time. Early drug discontinuation allowed a fast resolution of the serous detachment but the typical RPE pigment mottling observed at the resolution phase was noticed 1 week later.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372319     DOI: 10.1097/ICB.0000000000000013

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  6 in total

Review 1.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

Review 2.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048

3.  Presumed Chemotherapy-Induced Optic Neuropathy and Maculopathy: A Case Report.

Authors:  David J Mathew; Anupriya Arthur; Sheeja Susan John
Journal:  Open Ophthalmol J       Date:  2017-09-30

4.  Unilateral macular choroidal neovascularization-a rare manifestation in acute myelocytic leukemia: Case report.

Authors:  Xiaochun Yang; Jianbiao Xu; Jianhui Yang; Yikun Zhou; Yan Mei; Tonghua Yang; Yangmo Zhang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

5.  Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature.

Authors:  Mohamed Belmouhand; Christina Eckmann-Hansen; Tomas Ilginis; Eva Birgitte Leinøe; Bo Kok Mortensen; Michael Larsen
Journal:  BMC Ophthalmol       Date:  2021-07-13       Impact factor: 2.209

6.  Retinal and Choriocapillaris Vascular Changes in Patients Affected by Different Clinical Phenotypes of β-Thalassemia: An Optical Coherence Tomography Angiography Study.

Authors:  Gilda Cennamo; Daniela Montorio; Giuliano Mazzella; Paolo Ricchi; Silvia Costantini; Anna Spasiano; Aldo Filosa; Maria Rosaria Storino; Francesca Aquila; Fausto Tranfa; Michela Grosso
Journal:  Biology (Basel)       Date:  2021-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.